Savara

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Savara and other ETFs, options, and stocks.

About SVRA

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis.

CEO

Matthew Pauls

CEOMatthew Pauls

Employees

Employees70

Headquarters

Langhorne, Pennsylvania

HeadquartersLanghorne, Pennsylvania

Founded

1995

Founded1995

Employees

Employees70

SVRA Key Statistics

Market cap

1.03B

Market cap1.03B

Price-Earnings ratio

-9.64

Price-Earnings ratio-9.64

Dividend yield

—

Dividend yield—

Average volume

1.38M

Average volume1.38M

High today

$5.12

High today$5.12

Low today

$4.95

Low today$4.95

Open price

$5.12

Open price$5.12

Volume

1.29M

Volume1.29M

52 Week high

$7.01

52 Week high$7.01

52 Week low

$1.89

52 Week low$1.89

Stock Snapshot

Savara(SVRA) stock is priced at $5.04, giving the company a market capitalization of 1.03B. It carries a P/E multiple of -9.64.

On 2026-03-18, Savara(SVRA) stock moved within a range of $4.95 to $5.12. With shares now at $5.04, the stock is trading +1.7% above its intraday low and -1.7% below the session's peak.

Trading volume for Savara(SVRA) stock has reached 1.29M, versus its average volume of 1.38M.

The stock's 52-week range extends from a low of $1.89 to a high of $7.01.

SVRA News

TipRanks 2d

De-Risked Path to Market and Concentrated Rare Disease Opportunity Support Buy Rating on Savara’s Molbreevi

Savara, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on the sto...

TipRanks 5d

Savara Signs Long-Term Lease for New Headquarters

Savara ( (SVRA) ) has provided an update. On March 10, 2026, Savara Inc. signed a lease with ML7 Yardley Partners, LP for about 10,795 square feet of office sp...

TipRanks 5d

Savara reports Q4 EPS (13c), consensus (12c)

As of December 31, 2025, the company had cash, cash equivalents and short-term investments of $235.7M. “Over the last year, we significantly advanced the MOLBRE...

Analyst ratings

100%

of 8 ratings

Buy

100%

Hold

Sell

People also own

Based on the portfolios of people who own SVRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.